Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | PRESIDENT AND CSO | June 05, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2034-06-04 | Direct | 150,000 |
Reported balance
After 2024-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 150,000 · Balance 150,000 F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 7, 2024 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000950170-24-070564 · ownership.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0000950170-24-028611 · ownership.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 4,000 | $2.76 | $11,040.00 |
DisclosureSEC source: 0001209191-23-047575 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,638 Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 124,125 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-043273 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,125 Underlying: Common Stock · 124,125 shares Expires 2033-07-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:01 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 125,500 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-23-011255 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,500 Underlying: Common Stock · 125,500 shares Expires 2033-02-15 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:31 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 16,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-022578 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on March 31, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on March 31, 2020. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:31 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 7,068 | $4.88 | $34,491.84 |
DisclosureSEC source: 0001209191-22-022578 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,638 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:31 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 16,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-022578 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:15 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 21,333 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-22-021458 · doc4.xml · derivative · entry 2 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,333 Underlying: Common Stock · 21,333 shares Expires 2032-03-24 F2 · derivative.exercise_date: 2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. F2 · derivative.expiration_date: 2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. Read SEC document |
| February 09, 2022 Filed Mar 29, 2022 20:15 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 82,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001209191-22-021458 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2032-02-08 F1 · derivative.exercise_date: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 9, 2022. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0000899243-21-045069 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 8,000 shares Expires 2025-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning November 14, 2018. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 8,000 | $18.05 | $144,400.00 |
DisclosureSEC source: 0000899243-21-045069 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,038 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.21, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 8,000 | $8.26 | $66,080.00 |
DisclosureSEC source: 0000899243-21-045069 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-21-044603 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F3 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 20,000 | $15.07 | $301,354.00 |
DisclosureSEC source: 0000899243-21-044603 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,038 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 22:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 20,000 | $6.42 | $128,400.00 |
DisclosureSEC source: 0000899243-21-044603 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. Read SEC document |
| October 06, 2021 Filed Oct 8, 2021 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 14,134 | $12.97 | $183,317.98 |
DisclosureSEC source: 0001209191-21-060021 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,038 Read SEC document |
| October 03, 2021 Filed Oct 8, 2021 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060021 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. F3 · derivative.expiration_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| October 03, 2021 Filed Oct 8, 2021 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 33,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060021 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-21-057785 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F3 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 20,000 | $15.23 | $304,646.00 |
DisclosureSEC source: 0001209191-21-057785 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,838 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.58, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 20:30 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 20,000 | $6.42 | $128,400.00 |
DisclosureSEC source: 0001209191-21-057785 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · PRESIDENT AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:49 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006360 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 21:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 9,800 | $16.30 | $159,740.00 |
DisclosureSEC source: 0000899243-20-027608 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,091 Read SEC document |
| October 03, 2020 Filed Oct 6, 2020 21:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027608 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. F3 · derivative.expiration_date: On October 3, 2019, the reporting person was granted 100,000 restricted stock units, scheduled to vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| October 03, 2020 Filed Oct 6, 2020 21:08 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027608 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 800 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045698 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 800 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 800 | $20.01 | $16,008.00 |
DisclosureSEC source: 0001209191-20-045698 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:41 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 800 | $6.42 | $5,136.00 |
DisclosureSEC source: 0001209191-20-045698 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · derivative · entry 8 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,800 Underlying: Common Stock · 400 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 400 | $20.14 | $8,056.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 5 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.11 to $20.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 400 | $6.42 | $2,568.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 4 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 3,800 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · derivative · entry 7 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,200 Underlying: Common Stock · 3,800 shares Expires 2029-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · derivative · entry 6 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 2,000 shares Expires 2025-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning November 14, 2018. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 5,800 | $20.01 | $116,058.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 3,800 | $6.42 | $24,396.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 2,000 | $8.26 | $16,520.00 |
DisclosureSEC source: 0001209191-20-045142 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · derivative · entry 4 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,001 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. F2 · derivative.expiration_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,667 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. F2 · derivative.expiration_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 5,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 21:51 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008800 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:34 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054991 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. F2 · derivative.expiration_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. F2 · derivative.underlying: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:34 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 12,087 | $8.63 | $104,310.81 |
DisclosureSEC source: 0001209191-19-054991 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,246 Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:34 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054991 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-052713 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. F3 · derivative.expiration_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 400,000 | $7.53 Strike: $7.53 | $3,012,000.00 |
DisclosureSEC source: 0001209191-19-052713 · doc4.xml · derivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning April 3, 2020. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:16 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-19-018090 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-07-23 F2 · derivative.exercise_date: Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:16 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018090 · doc4.xml · derivative · entry 2 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 23:25 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 2,000 | $4.37 | $8,740.00 |
DisclosureSEC source: 0001209191-18-064128 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.